United States Oncology Diagnostics Market 2016-2017 – Forecast to 2021 – Markets Insider

Posted: August 12, 2017 at 4:44 am

DUBLIN, August 11, 2017 /PRNewswire/ —

The “US Oncology Diagnostics Market – Forecast to 2021” report has been added to Research and Markets’ offering.

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories.

Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes.

Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States.

The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung.

Highlights of the report include:

Key questions this study will answer include:

Key Topics Covered:

1. Executive Summary

2. US Oncology Diagnostics Market Overview

3. Overview of Competitors

4. Total Cancer Diagnostics Market

5. Breast Cancer

6. Ovarian Cancer

7. Cervical Cancer

8. Colorectal Cancer

9. Prostate Cancer

10. Lung Cancer

11. Companion Biomarker Opportunities in Drug Development

12. Future Outlook and Emerging Opportunities

13. Appendix

Companies Mentioned

For more information about this report visit: https://www.researchandmarkets.com/research/trsr3d/us_oncology

Media Contact:Research and Markets Laura Wood, Senior Manager rel=”nofollow”>press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Follow this link:
United States Oncology Diagnostics Market 2016-2017 – Forecast to 2021 – Markets Insider

Related Post